Rong Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rong Deng has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Bing Zhou
Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center of Translational Medicine for Cardiovascular Disease, and Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China
1 shared publication Chao Yue
Colorectal Cancer Center, Department of General Surgery, Jiangsu Cancer Hospital, Cancer Research Institute, Cancer hospital of Nanjing Medical University, Nanjing 210009, Jiangsu Province, PR China
1 shared publication- Da Wei
Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China
1 shared publication - Dongming Su
Center of Metabolic Research, Nanjing Medical University, Nanjing, China
1 shared publication - Haitao Zhu
Colorectal cancer center, general surgery department, Jiangsu province cancer hospital, Affiliated Cancer hospital of NanJing Medical University, Jiangsu Cancer Institute, No 42, Baiziting road, NanJing, Nanjing, Jiangsu, People's Republic of China, 210009.
1 shared publication - Jing Xu
Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
1 shared publication
Latest Publications
- Open Access
- 12 January 2022
- Published by Hindawi Limited in Computational and Mathematical Methods in Medicine
- Vol. 2022, 1-18
miR-641 Inhibited Cell Proliferation and Induced Apoptosis by Targeting NUCKS1/PI3K/AKT Signaling Pathway in Breast Cancer
Objective. Studies revealed an important role of microRNAs (miRNAs) in multiple cancers, including breast cancer. In the present study, we evaluated the role and function of miR-641 in breast cancer. Methods. The expression level of miR-641 in breast cancer cell lines (Hs-578T, MCF7, HCC1937, and MAD-MB-231) was determined by real-time PCR. Functional analyses, including CCK-8 assay, transwell assay, wound-healing assay, and apoptosis detection, were carried out to explore the roles of miRNA-641 in malignant behaviors of breast cancer. Luciferase report assay was used to investigate the regulatory association of miRNA-641 with its potential targets. Results. The expression levels of miR-641 were downregulated, while the expression levels of nuclear casein kinase and cyclin-dependent kinase substrate 1 (NUCKS1) were increased in breast cancer cell lines. The in vitro results showed that miR-641 repressed proliferation and migration/invasion and promoted apoptosis of breast cancer cells. NUCKS1, a positive regulator of phosphatidylinositol-3-kinases (PI3K)/protein-serine-threonine kinase (AKT) pathway, was confirmed as a direct target of miR-641. The of treatment of the PI3K agonist, 740Y-P, could abrogate the antioncogenic potentials of miR-641 in breast cancer cells. Conclusion. miR-641 functioned as a tumor suppressor through the PI3K/AKT signaling pathway via targeting NUCKS1 in breast cancer.
- 12 January 2022
- Published by Hindawi Limited in Computational and Mathematical Methods in Medicine
- Vol. 2022, 1-18
Open AccessmiR-641 Inhibited Cell Proliferation and Induced Apoptosis by Targeting NUCKS1/PI3K/AKT Signaling Pathway in Breast Cancer
Objective. Studies revealed an important role of microRNAs (miRNAs) in multiple cancers, including breast cancer. In the present study, we evaluated the role and function of miR-641 in breast cancer. Methods. The expression level of miR-641 in breast cancer cell lines (Hs-578T, MCF7, HCC1937, and MAD-MB-231) was determined by real-time PCR. Functional analyses, including CCK-8 assay, transwell assay, wound-healing assay, and apoptosis detection, were carried out to explore the roles of miRNA-641 in malignant behaviors of breast cancer. Luciferase report assay was used to investigate the regulatory association of miRNA-641 with its potential targets. Results. The expression levels of miR-641 were downregulated, while the expression levels of nuclear casein kinase and cyclin-dependent kinase substrate 1 (NUCKS1) were increased in breast cancer cell lines. The in vitro results showed that miR-641 repressed proliferation and migration/invasion and promoted apoptosis of breast cancer cells. NUCKS1, a positive regulator of phosphatidylinositol-3-kinases (PI3K)/protein-serine-threonine kinase (AKT) pathway, was confirmed as a direct target of miR-641. The of treatment of the PI3K agonist, 740Y-P, could abrogate the antioncogenic potentials of miR-641 in breast cancer cells. Conclusion. miR-641 functioned as a tumor suppressor through the PI3K/AKT signaling pathway via targeting NUCKS1 in breast cancer.
- 1 January 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 495 (1) , 539-545
Long non-coding RNA-422 acts as a tumor suppressor in colorectal cancer
- 1 January 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 495 (1) , 539-545
Long non-coding RNA-422 acts as a tumor suppressor in colorectal cancer